Literature DB >> 9651855

An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital.

A S Breathnach1, A de Ruiter, G M Holdsworth, N T Bateman, D G O'Sullivan, P J Rees, D Snashall, H J Milburn, B S Peters, J Watson, F A Drobniewski, G L French.   

Abstract

We describe the epidemiology and control of a hospital outbreak of multi-drug-resistant tuberculosis (MDR-TB). A human immunodeficiency virus (HIV)-negative patient with drug-sensitive tuberculosis developed MDR-TB during a period of unsupervised therapy. She was admitted to an isolation room in a ward with HIV-positive patients, but the room, unbeknown to hospital staff, was at positive-pressure relative to the main ward. Seven HIV-positive contacts developed MDR-TB. The diagnosis in the second patient was delayed, partly because acid-fast bacilli in his sputum were assumed to be Mycobacterium avium-intracellulare. All the available Mycobacterium tuberculosis isolates were indistinguishable by molecular typing. Nearly 1400 staff and patient contacts were offered screening, but the screening programme detected only one of the cases. Despite therapy, the index patient and two of the contacts died. HIV-positive patients are more likely than others to develop tuberculosis after exposure, and the disease may progress more rapidly. In these patients the possibility that acid-fast bacilli may represent M. tuberculosis must always be considered. Patients with tuberculosis (suspected or proven) should not be nursed in the same wards as immunosuppressed patients, and should be isolated. MDR-TB cases must be isolated in negative-pressure rooms. Hospital side-rooms may be positive-pressure as a fire safety measure; infection control teams must be aware of the airflows in all isolation rooms, and must be consulted during the design of hospital buildings. Good communication between infection control teams and clinicians is important, and all medical and nursing staff must be aware of the principles of management of patients with proven or suspected tuberculosis and MDR-TB.

Entities:  

Mesh:

Year:  1998        PMID: 9651855     DOI: 10.1016/s0195-6701(98)90324-3

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  22 in total

Review 1.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  False molecular clusters due to nonrandom association of IS6110 with Mycobacterium tuberculosis.

Authors:  S H Gillespie; A Dickens; T D McHugh
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation.

Authors:  V Nikolayevsky; T Brown; Y Balabanova; M Ruddy; I Fedorin; F Drobniewski
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

4.  Diagnosing multidrug resistant tuberculosis in Britain. Clinical suspicion should drive rapid diagnosis.

Authors:  F A Drobniewski
Journal:  BMJ       Date:  1998-11-07

5.  Evolutionary relationships among strains of Mycobacterium tuberculosis with few copies of IS6110.

Authors:  Jeremy W Dale; Hasan Al-Ghusein; Salim Al-Hashmi; Philip Butcher; Anne L Dickens; Francis Drobniewski; Ken J Forbes; Stephen H Gillespie; Dianie Lamprecht; Timothy D McHugh; Richard Pitman; Nalin Rastogi; Andrew T Smith; Christophe Sola; Hasan Yesilkaya
Journal:  J Bacteriol       Date:  2003-04       Impact factor: 3.490

6.  Evaluation and utilization as a public health tool of a national molecular epidemiological tuberculosis outbreak database within the United Kingdom from 1997 to 2001.

Authors:  F A Drobniewski; A Gibson; M Ruddy; M D Yates
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

7.  A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK.

Authors:  F Drobniewski; I Eltringham; C Graham; J G Magee; E G Smith; B Watt
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

8.  Rifampin- and multidrug-resistant tuberculosis in Russian civilians and prison inmates: dominance of the beijing strain family.

Authors:  Francis Drobniewski; Yanina Balabanova; Michael Ruddy; Laura Weldon; Katya Jeltkova; Timothy Brown; Nadezdna Malomanova; Elvira Elizarova; Alexander Melentyey; Ebgeny Mutovkin; Svetlana Zhakharova; Ivan Fedorin
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

9.  Worldwide emergence of extensively drug-resistant tuberculosis.

Authors:  N Sarita Shah; Abigail Wright; Gill-Han Bai; Lucia Barrera; Fadila Boulahbal; Nuria Martín-Casabona; Francis Drobniewski; Chris Gilpin; Marta Havelková; Rosario Lepe; Richard Lumb; Beverly Metchock; Françoise Portaels; Maria Filomena Rodrigues; Sabine Rüsch-Gerdes; Armand Van Deun; Veronique Vincent; Kayla Laserson; Charles Wells; J Peter Cegielski
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

10.  Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis.

Authors:  Francine Matthys; Leen Rigouts; Vinciane Sizaire; Natalia Vezhnina; Maryvonne Lecoq; Vera Golubeva; Françoise Portaels; Patrick Van der Stuyft; Michael Kimerling
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.